November 23, 2021 -- Neurophth Therapeutics has raised over $60 million in series C financing to advance gene therapies for ophthalmic diseases.
Neurophth is an integrated genomics medicine company whose leading investors include CMG-SDIC Capital, Sequoia Capital China, Sunshine Insurance, and China Merchant Bank International Capital.
Neurophth's lead candidate, NR082 (rAAV-ND4, NFS-01), is the first adeno-associated virus 2-based gene therapy to receive investigational new drug application approval in China, with the first patient being dosed in June 2021. NR082, a gene therapy candidate for the treatment of ND4-mediated Leber hereditary optic neuropathy, has been also granted the orphan drug designation by the U.S. Food and Drug Administration.
Copyright © 2021 scienceboard.net